728 related articles for article (PubMed ID: 33937058)
21. High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial.
Cook G; Williams C; Brown JM; Cairns DA; Cavenagh J; Snowden JA; Ashcroft AJ; Fletcher M; Parrish C; Yong K; Cavet J; Hunter H; Bird JM; Chalmers A; O'Connor S; Drayson MT; Morris TC;
Lancet Oncol; 2014 Jul; 15(8):874-85. PubMed ID: 24948586
[TBL] [Abstract][Full Text] [Related]
22. A randomized phase II, open-label and multicenter study of combination regimens of bortezomib at two doses by subcutaneous injection for newly diagnosed multiple myeloma patients.
Li F; Yao FS; Zhu XJ; Gu WY; Wang XH; Chen B; Huang DP; Ding JH; Wu TQ; Zhu Y; Zhao Q; Tang YM; Song P; Zhou XG; An ZM; Guo X; Wang XL; Zhong L; Xie XB; Zhai YP
J Cancer Res Clin Oncol; 2019 Sep; 145(9):2343-2355. PubMed ID: 31280348
[TBL] [Abstract][Full Text] [Related]
23. Long-term outcomes of different bortezomib-based regimens in Chinese myeloma patients.
Wang H; Wang L; Lu Y; Chen X; Geng Q; Wang W; Xia Z
Onco Targets Ther; 2016; 9():587-95. PubMed ID: 26869803
[TBL] [Abstract][Full Text] [Related]
24. Bortezomib-based strategy with autologous stem cell transplantation for newly diagnosed multiple myeloma: a phase II study by the Japan Study Group for Cell Therapy and Transplantation (JSCT-MM12).
Sunami K; Matsumoto M; Fuchida SI; Omoto E; Takamatsu H; Adachi Y; Choi I; Fujishima N; Kiguchi T; Miyamoto T; Maeda A; Suzumiya J; Yamamura R; Nagafuji K; Nakazato T; Kuroda Y; Yujiri T; Takamatsu Y; Harada M; Akashi K
Int J Clin Oncol; 2019 Aug; 24(8):966-975. PubMed ID: 30937622
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety analysis of bortezomib-based triplet regimens sequential lenalidomide in newly diagnosed multiple myeloma patients.
Zhou Q; Xu F; Wen J; Yue J; Zhang Y; Su J; Liu Y
Clin Exp Med; 2023 Sep; 23(5):1573-1580. PubMed ID: 36094683
[TBL] [Abstract][Full Text] [Related]
26. Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDA.
Suzuki K; Wechalekar AD; Kim K; Shimazaki C; Kim JS; Ikezoe T; Min CK; Zhou F; Cai Z; Chen X; Iida S; Katoh N; Fujisaki T; Shin HJ; Tran N; Qin X; Vasey SY; Tromp B; Weiss BM; Comenzo RL; Kastritis E; Lu J
Ann Hematol; 2023 Apr; 102(4):863-876. PubMed ID: 36862168
[TBL] [Abstract][Full Text] [Related]
27. Treatment outcome and prognostic factor analysis in transplant-eligible Chinese myeloma patients receiving bortezomib-based induction regimens including the staged approach, PAD or VTD.
Chim CS; Lie AK; Chan EY; Liu HS; Lau CW; Yip SF; Sim J; Wan TS; Ma ES; Liang R; Tse E; Kwong YL;
J Hematol Oncol; 2012 Jun; 5():28. PubMed ID: 22682027
[TBL] [Abstract][Full Text] [Related]
28. Bortezomib-cyclophosphamide-dexamethasone induction/consolidation and bortezomib maintenance for transplant-eligible newly diagnosed multiple myeloma: phase 2 multicenter trial.
Muranushi H; Kanda J; Kobayashi M; Maeda T; Kitano T; Tsuji M; Ueda Y; Ishikawa T; Nohgawa M; Watanabe M; Imada K; Moriguchi T; Itoh M; Ohno H; Yonezawa A; Hirata H; Arima N; Asagoe K; Anzai N; Nagata K; Yasuno S; Kuwabara Y; Kitao H; Kim I; Kawagishi K; Ueshima K; Tominari S; Nakayama T; Yamashita K; Takaori-Kondo A
Hematology; 2022 Dec; 27(1):239-248. PubMed ID: 35152852
[TBL] [Abstract][Full Text] [Related]
29. Comparison of efficacy, safety, patients' quality of life, and doctors' occupational stress between lenalidomide-based and bortezomib-based induction in patients with newly diagnosed multiple myeloma.
Xu L; Liu J; Huang B; Kuang L; Gu J; Chen M; Zou W; Li J
Cancer Med; 2021 Mar; 10(5):1656-1667. PubMed ID: 33527753
[TBL] [Abstract][Full Text] [Related]
30. Impact of Induction With VCD Versus VRD on the Outcome of Patients With Multiple Myeloma After an Autologous Hematopoietic Stem Cell Transplantation.
Afrough A; Pasvolsky O; Ma J; Srour S; Bashir Q; Saini N; Hosing C; Popat UR; Kebriaei P; Delgado R; Ullah MR; Murphy R; Manasanch EE; Lee HC; Kaufman GP; Patel KK; Thomas SK; Weber DM; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH
Transplant Cell Ther; 2022 Jun; 28(6):307.e1-307.e8. PubMed ID: 35331973
[TBL] [Abstract][Full Text] [Related]
31. [Outcomes of AL-amyloidosis treatment with bortezomib, dexamethasone and cyclophosphamide or doxorubicin-containing regimens].
Adam Z; Stork M; Pour L; Krejčí M; Zahradová L; Sandecká V; Hájek R; Cermáková Z; Pospíšilová Y; Navrátil M; Král Z; Mayer J
Vnitr Lek; 2012 Dec; 58(12):896-903. PubMed ID: 23427947
[TBL] [Abstract][Full Text] [Related]
32. Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma.
Palumbo A; Gay F; Bringhen S; Falcone A; Pescosta N; Callea V; Caravita T; Morabito F; Magarotto V; Ruggeri M; Avonto I; Musto P; Cascavilla N; Bruno B; Boccadoro M
Ann Oncol; 2008 Jun; 19(6):1160-5. PubMed ID: 18326520
[TBL] [Abstract][Full Text] [Related]
33. Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUK
Yong KL; Hinsley S; Auner HW; Bygrave C; Kaiser MF; Ramasamy K; De Tute RM; Sherratt D; Flanagan L; Garg M; Hawkins S; Williams C; Cavenagh J; Rabin NK; Croft J; Morgan G; Davies F; Owen RG; Brown SR
Haematologica; 2021 Oct; 106(10):2694-2706. PubMed ID: 33910333
[TBL] [Abstract][Full Text] [Related]
34. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma.
Kumar S; Flinn I; Richardson PG; Hari P; Callander N; Noga SJ; Stewart AK; Turturro F; Rifkin R; Wolf J; Estevam J; Mulligan G; Shi H; Webb IJ; Rajkumar SV
Blood; 2012 May; 119(19):4375-82. PubMed ID: 22422823
[TBL] [Abstract][Full Text] [Related]
35. Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trial.
Einsele H; Engelhardt M; Tapprich C; Müller J; Liebisch P; Langer C; Kropff M; Mügge LO; Jung W; Wolf HH; Metzner B; Hart C; Gramatzki M; Hertenstein B; Pfreundschuh M; Rösler W; Fischer T; Maschmeyer G; Kanz L; Hess G; Jäger E; Bentz M; Dürk HA; Salwender H; Hebart H; Straka C; Knop S
Br J Haematol; 2017 Nov; 179(4):586-597. PubMed ID: 28961309
[TBL] [Abstract][Full Text] [Related]
36. A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma.
Griffin PT; Ho VQ; Fulp W; Nishihori T; Shain KH; Alsina M; Baz RC
Cancer; 2015 Oct; 121(20):3622-30. PubMed ID: 26149422
[TBL] [Abstract][Full Text] [Related]
37. [Adverse effects of PAD and VAD regimens in multiple myeloma patients].
Zhao Y; Jing Y; Bo J; Li HH; Wang SH; Huang WR; Zhu HY; Han XP; Dou LP; Wang FF; Li F; Gao CJ; Wang QS; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Aug; 18(4):1027-30. PubMed ID: 20723322
[TBL] [Abstract][Full Text] [Related]
38. Comparison of engraftment following different stem cell mobilization modalities in patients with multiple myeloma treated with a uniform induction regimen containing bortezomib, cyclophosphamide and dexamethasone.
Benyamini N; Avivi I; Dann EJ; Zuckerman T; Lavi N; Katz T
Ann Hematol; 2017 Mar; 96(3):461-467. PubMed ID: 28013359
[TBL] [Abstract][Full Text] [Related]
39. VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial.
Moreau P; Hulin C; Macro M; Caillot D; Chaleteix C; Roussel M; Garderet L; Royer B; Brechignac S; Tiab M; Puyade M; Escoffre M; Stoppa AM; Facon T; Pegourie B; Chaoui D; Jaccard A; Slama B; Marit G; Laribi K; Godmer P; Luycx O; Eisenmann JC; Allangba O; Dib M; Araujo C; Fontan J; Belhadj K; Wetterwald M; Dorvaux V; Fermand JP; Rodon P; Kolb B; Glaisner S; Malfuson JV; Lenain P; Biron L; Planche L; Caillon H; Avet-Loiseau H; Dejoie T; Attal M
Blood; 2016 May; 127(21):2569-74. PubMed ID: 27002117
[TBL] [Abstract][Full Text] [Related]
40. [Bortezomib-based triple combinations (VCD, PAD) for untreated patients with multiple myeloma].
Izumi T
Nihon Rinsho; 2015 Feb; 73 Suppl 2():646-8. PubMed ID: 25831840
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]